GLP-1 Receptor Agonists vs SGLT2 Inhibitors for T2DM GLP-1 Receptor Agonists vs SGLT2 Inhibitors for T2DM
How do these treatments for type 2 diabetes compare in terms of cardiovascular and renal outcomes and risk for adverse events?Journal of the Endocrine Society (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - June 16, 2020 Category: Consumer Health News Tags: Diabetes & Endocrinology Journal Article Source Type: news

Those Most in Need Least Likely to Get Newer Diabetes Medications Those Most in Need Least Likely to Get Newer Diabetes Medications
Racial and socioeconomic disparities may be impeding access to newer diabetes medications, including DPP-4 inhibitors, GLP-1 agonists, and SGLT2 inhibitors, among US patients.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 14, 2020 Category: Consumer Health News Tags: Diabetes & Endocrinology News Source Type: news

EMPA-REG OUTCOME: Empagliflozin Cuts Insulin Need in Type 2 Diabetes EMPA-REG OUTCOME: Empagliflozin Cuts Insulin Need in Type 2 Diabetes
The SGLT2 inhibitor reduced the need to start insulin treatment or intensify existing insulin treatment compared with placebo in a post-hoc analysis.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 14, 2020 Category: Consumer Health News Tags: Diabetes & Endocrinology News Source Type: news

SGLT2 Inhibitors vs GLP-1 Agonists for Diabetes in Real-World Study SGLT2 Inhibitors vs GLP-1 Agonists for Diabetes in Real-World Study
Compared with GLP-1 agonists, SGLT2 inhibitors were linked with similar cardiovascular outcomes but less heart failure, treatment discontinuation, healthcare use, and cost in a new study.Medscape Medical News (Source: Medscape Diabetes Headlines)
Source: Medscape Diabetes Headlines - June 14, 2020 Category: Endocrinology Tags: Diabetes & Endocrinology News Source Type: news

Dapagliflozin Benefits in HF Regardless of Diuretics: DAPA-HF Dapagliflozin Benefits in HF Regardless of Diuretics: DAPA-HF
The trial that turned an SGLT2 inhibitor into a heart failure drug also has clues to mechanisms behind the observed benefits. Contrary to early speculation, diuresis may be off the list.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - June 10, 2020 Category: Cardiology Tags: Cardiology News Source Type: news

EU Green Light for Canagliflozin to Slow Diabetic Kidney Disease EU Green Light for Canagliflozin to Slow Diabetic Kidney Disease
The CHMP has recommended approval for the SGLT2 inhibitor canagliflozin (Invokana) be extended to include diabetic kidney disease.International Approvals (Source: Medscape Transplantation Headlines)
Source: Medscape Transplantation Headlines - June 1, 2020 Category: Transplant Surgery Tags: Diabetes & Endocrinology News Alert Source Type: news

Type 2 Diabetes Update: Semaglutide and Linagliptin as Basal Insulin Alternatives
Cardiovascular comorbidities and risk reduction play a major new role in pharmacologic therapy for type 2 diabetes, with sodium-glucose transporter 2 (SGLT2) inhibitors and glucagon-like peptide 1 (GLP-1) receptor agonists now recommended as part of the glucose-lowering regimen for patients who have established atherosclerotic cardiovascular disease (ASCVD) or indicators of high-risk, chronic kidney disease (CKD) or heart failure (HF). (Source: Caring for the Ages)
Source: Caring for the Ages - May 31, 2020 Category: Health Management Authors: Christine Kilgore Source Type: news

DCRI-collaboration-empact-mi
Boehringer Ingelheim and Lilly to collaborate with Duke Clinical Research Institute on a pragmatic trial examining empagliflozin ’s effects following an acute myocardial infarction Ischemic heart disease, including myocardial infarction, is the leading cause of death in the world1EMPACT-MI is the first trial in the SGLT2 inhibitor class to investigate the prevention of heart failure after acute myocardial infarction in adults with and without diabetesThe trial is part of the EMPOWER clinical trial program, the broadest and most comprehensive of any SGLT2 inhibitor, exploring the impact of empagliflozin on the lives of p...
Source: Boehringer Ingelheim Corporate News - May 26, 2020 Category: Research Source Type: news

Call for More Transparency in Gray Area of Post-Approval Drug Studies Call for More Transparency in Gray Area of Post-Approval Drug Studies
' Post-market safety studies are often inadequate, not completed, and poorly reported in the public arena, ' say the authors of study examining SGLT2 inhibitors. But clinicians say this is not so black and white.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - May 6, 2020 Category: Consumer Health News Tags: Diabetes & Endocrinology News Source Type: news

SGLT2 Inhibitors May Prevent Diabetic Kidney Disease SGLT2 Inhibitors May Prevent Diabetic Kidney Disease
Patients with type 2 diabetes in real-world practice who received an SGLT2 inhibitor rather than a DPP-4 inhibitor were less likely to develop serious renal events, consistent with clinical trial findings.Medscape Medical News (Source: Medscape Diabetes Headlines)
Source: Medscape Diabetes Headlines - May 4, 2020 Category: Endocrinology Tags: Diabetes & Endocrinology News Source Type: news

SGLT2 Inhibitors Linked to Reduced Risk for Serious Renal Events
FRIDAY, May 1, 2020 -- Use of sodium-glucose cotransporter 2 (SGLT2) inhibitors is associated with a reduced risk for serious renal events compared with dipeptidyl peptidase-4 inhibitors, according to a study published online April 29 in The... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - May 1, 2020 Category: Pharmaceuticals Source Type: news

Sodium-Glucose Transporter-2 Inhibition: An Important Advancement for...
In this free webinar, the speakers will review SGLT2 inhibitors and present emerging data on SGLT2 inhibitors and the impact on patients with type 2 DM and CKD.(PRWeb March 23, 2020)Read the full story at https://www.prweb.com/releases/sodium_glucose_transporter_2_inhibition_an_important_advancement_for_patients_with_type_2_diabetes_and_chronic_kidney_disease_upcoming_webinar_hosted_by_xtalks/prweb16996158.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - March 23, 2020 Category: Pharmaceuticals Source Type: news

Janssen Highlights Continued Commitment to Cardiovascular & Metabolic Healthcare Solutions with Late-Breaking Data at the First Fully Virtual American College of Cardiology Scientific Session
RARITAN, N.J., March 20, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that it will unveil late-breaking data from its leading cardiovascular and metabolism portfolio during the virtual American College of Cardiology’s 69th Annual Scientific Session together with the World Congress of Cardiology (ACC.20/WCC) on March 28-30, 2020. Notably, four late-breaking abstracts for XARELTO® (rivaroxaban) will be presented, including data from the Phase 3 VOYAGER PAD study in patients with symptomatic peripheral artery disease (PAD) after lower-extremity revascularization.Click to Tweet: Jan...
Source: Johnson and Johnson - March 20, 2020 Category: Pharmaceuticals Source Type: news

FDA revises labels of SGLT2 inhibitors for diabetes to include warnings about too much acid in the blood and serious urinary tract infections
A U.S. Food and Drug Administration (FDA) safety review has resulted in adding warnings to the labels of a specific class of type 2 diabetes medicines called sodium-glucose cotransporter-2 (SGLT2) inhibitors about the risks of too much acid in the blood and of serious urinary tract infections. Both conditions can result in hospitalization. (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - March 19, 2020 Category: Drugs & Pharmacology Authors: FDA Source Type: news

FDA Says Stop SGLT2 Inhibitors for Diabetes Prior to Surgery FDA Says Stop SGLT2 Inhibitors for Diabetes Prior to Surgery
Label changes were approved by the FDA as surgery may put patients being treated with SGLT2 inhibitors at higher risk of ketoacidosis.Medscape Medical News (Source: Medscape Orthopaedics Headlines)
Source: Medscape Orthopaedics Headlines - March 18, 2020 Category: Orthopaedics Tags: Diabetes & Endocrinology News Source Type: news